Pfizer Inc. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 9, 2024, to register an additional 320 million shares of common stock under its Amended and Restated 2019 Stock Plan. This move follows the approval by Pfizer's shareholders at the Annual Meeting on April 25, 2024, to authorize the additional shares for issuance under the Plan. The registration statement incorporates by reference the contents of Pfizer’s effective registration statements on Form S-8 filed previously with the SEC. The documents required for the registration statement will be delivered to participants in the Plan as specified by the SEC rules and are available upon request. The registration statement includes references to Pfizer's recent financial reports and other filings with the SEC, which are incorporated by reference and provide updated information to the SEC and investors.

Pfizer Inc. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 9, 2024, to register an additional 320 million shares of common stock under its Amended and Restated 2019 Stock Plan. This move follows the approval by Pfizer's shareholders at the Annual Meeting on April 25, 2024, to authorize the additional shares for issuance under the Plan. The registration statement incorporates by reference the contents of Pfizer’s effective registration statements on Form S-8 filed previously with the SEC. The documents required for the registration statement will be delivered to participants in the Plan as specified by the SEC rules and are available upon request. The registration statement includes references to Pfizer's recent financial reports and other filings with the SEC, which are incorporated by reference and provide updated information to the SEC and investors.